Anna Polli
- Oncology top 1%
- Lung Cancer Research Studies 27
- Colorectal Cancer Treatments and Studies 22
- Cancer Treatment and Pharmacology 6
-
- Lung Cancer Treatments and Mutations 52
- Lung Cancer Diagnosis and Treatment 22
- Gastric Cancer Management and Outcomes 8
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 9
- Genetics top 2%
- Estrogen and related hormone effects 16
Anna Polli
72 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 2.5k
- Pulmonary and Respiratory Medicine 2.3k
- Cancer Research 943
- Genetics 1.0k
- Endocrinology, Diabetes and Metabolism 591
Countries citing papers authored by Anna Polli
This map shows the geographic impact of Anna Polli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Polli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Polli more than expected).
Fields of papers citing papers by Anna Polli
This network shows the impact of papers produced by Anna Polli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Polli. The network helps show where Anna Polli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anna Polli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Studybreakdown → | 2024 | 118 |
| 4 | 2024 | 0 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 3 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 22 | |
| 10 | 2023 | 26 | |
| 11 | 2022 | 12 | |
| 12 | 2022 | 5 | |
| 13 | Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studybreakdown → | 2022 | 129 |
| 14 | 2021 | 2 | |
| 15 | First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancerbreakdown → | 2020 | 649 |
| 16 | 2018 | 12 | |
| 17 | 2017 | 45 | |
| 18 | 2016 | 2 | |
| 19 | 2006 | 84 | |
| 20 | 2000 | 25 |
About Anna Polli
Anna Polli is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Pathology and Forensic Medicine, having authored 80 papers that have together received 4.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (27 papers), Colorectal Cancer Treatments and Studies (22 papers), Lung Cancer Diagnosis and Treatment (22 papers), Estrogen and related hormone effects (16 papers), Cancer Genomics and Diagnostics (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Oncology (2.5k citations), Pulmonary and Respiratory Medicine (2.3k citations), Cancer Research (943 citations), Genetics (1.0k citations) and Endocrinology, Diabetes and Metabolism (591 citations). Anna Polli has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Alice T. Shaw, Benjamin Solomon, G. Piscitelli, Tony Mok, Carlo Ferrari, Jonathan Webster, Ikram Shah Ismail, M. F. Scanlon, Dong‐Wan Kim and Giorgio Massimini. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.